Jefferies Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $419K | Buy |
1,447
+331
| +30% | +$95.2K | ﹤0.01% | 1098 |
|
|
2022
Q2 | $314K | Buy |
1,116
+366
| +49% | +$98K | ﹤0.01% | 1154 |
|
|
2022
Q1 | $196K | Sell |
750
-4,125
| -85% | -$979K | ﹤0.01% | 1271 |
|
|
2021
Q4 | $1.07M | Sell |
4,875
-20,191
| -81% | -$3.93M | 0.01% | 984 |
|
|
2021
Q3 | $4.55M | Buy |
25,066
+8,427
| +51% | +$1.65M | 0.03% | 466 |
|
|
2021
Q2 | $3.35M | Buy |
16,639
+6,945
| +72% | +$1.45M | 0.02% | 579 |
|
|
2021
Q1 | $2.08M | Buy |
9,694
+8,772
| +951% | +$1.93M | 0.02% | 668 |
|
|
2020
Q4 | $218K | Buy |
922
+158
| +21% | +$36.3K | ﹤0.01% | 1359 |
|
|
2020
Q3 | $208K | Buy |
+764
| New | +$211K | ﹤0.01% | 1179 |
|
|
2020
Q2 | – | Sell |
-966
| Closed | -$230K | – | 2076 |
|
|
2020
Q1 | $230K | Sell |
966
-16,614
| -95% | -$3.81M | ﹤0.01% | 1632 |
|
|
2019
Q4 | $3.85M | Sell |
17,580
-20,944
| -54% | -$4.24M | 0.03% | 649 |
|
|
2019
Q3 | $6.53M | Buy |
38,524
+23,646
| +159% | +$4.18M | 0.05% | 389 |
|
|
2019
Q2 | $2.73M | Buy |
14,878
+9,385
| +171% | +$1.64M | 0.02% | 768 |
|
|
2019
Q1 | $1.01M | Buy |
5,493
+3,024
| +122% | +$559K | 0.01% | 1268 |
|
|
2018
Q4 | $409K | Sell |
2,469
-1,217
| -33% | -$211K | ﹤0.01% | 1535 |
|
|
2018
Q3 | $710K | Sell |
3,686
-38,586
| -91% | -$6.87M | ﹤0.01% | 1485 |
|
|
2018
Q2 | $7.18M | Buy |
42,272
+13,178
| +45% | +$2.04M | 0.04% | 367 |
|
|
2018
Q1 | $4.74M | Buy |
29,094
+28,940
| +18,792% | +$4.73M | 0.03% | 491 |
|
|
2017
Q4 | $23K | Sell |
154
-34,146
| -100% | -$5.06M | ﹤0.01% | 2419 |
|
|
2017
Q3 | $5.21M | Sell |
34,300
-3,089
| -8% | -$465K | 0.03% | 515 |
|
|
2017
Q2 | $4.82M | Sell |
37,389
-49,606
| -57% | -$5.97M | 0.03% | 548 |
|
|
2017
Q1 | $9.51M | Buy |
86,995
+70,587
| +430% | +$6.21M | 0.07% | 280 |
|
|
2016
Q4 | $1.21M | Buy |
16,408
+1,039
| +7% | +$84.5K | 0.01% | 1167 |
|
|
2016
Q3 | $1.34M | Buy |
+15,369
| New | +$1.45M | 0.01% | 1131 |
|
|
2016
Q2 | – | Sell |
-29,613
| Closed | -$2.35M | – | 2464 |
|
|
2016
Q1 | $2.35M | Buy |
29,613
+23,835
| +413% | +$2.16M | 0.01% | 777 |
|
|
2015
Q4 | $727K | Sell |
5,778
-30,424
| -84% | -$3.67M | ﹤0.01% | 1329 |
|
|
2015
Q3 | $3.77M | Buy |
36,202
+36,052
| +24,035% | +$4.63M | 0.02% | 614 |
|
|
2015
Q2 | $19K | Hold |
150
| – | – | ﹤0.01% | 2634 |
|
|
2015
Q1 | $18K | Sell |
150
-129,367
| -100% | -$15.5M | ﹤0.01% | 1984 |
|
|
2014
Q4 | $15.4M | Buy |
129,517
+127,271
| +5,667% | +$14.3M | 0.09% | 191 |
|
|
2014
Q3 | $252K | Sell |
2,246
-14,038
| -86% | -$1.34M | ﹤0.01% | 1703 |
|
|
2014
Q2 | $1.54M | Sell |
16,284
-16,353
| -50% | -$1.15M | 0.01% | 731 |
|
|
2014
Q1 | $2.31M | Buy |
32,637
+29,574
| +966% | +$2.34M | 0.02% | 562 |
|
|
2013
Q4 | $227K | Buy |
+3,063
| New | +$213K | ﹤0.01% | 1523 |
|
|
2013
Q3 | – | Sell |
-10,758
| Closed | -$861K | – | 2210 |
|
|
2013
Q2 | $861K | Buy |
+10,758
| New | +$792K | 0.01% | 834 |
|
Other funds holding VRTX
Jefferies Group's VRTX Position: Q3 2022 in Review
Jefferies Group increased its Vertex Pharmaceuticals (VRTX) stake by 30% in Q3 2022, buying an estimated $95.2K and bringing the position to 1,447 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #1098.
Jefferies Group first reported a position in VRTX in Q2 2013 and has held it in 35 quarters since. The position peaked at $15.4M in Q4 2014. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.
- Jefferies Group held 1,447 shares of Vertex Pharmaceuticals worth $419K as of Q3 2022.
- Jefferies Group bought 331 Vertex Pharmaceuticals shares in Q3 2022, an estimated $95.2K.
- Vertex Pharmaceuticals made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1098 holding.
- Jefferies Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
- Jefferies Group's Vertex Pharmaceuticals position peaked at $15.4M in Q4 2014.
- 1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.